Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 13.4% – What’s Next?

Burning Rock Biotech Limited (NASDAQ:BNR) shares fell 13.4% on Monday . The stock traded as low as $4.90 and last traded at $4.90. 7,883 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 13,817 shares. The stock had previously closed at $5.66.

Burning Rock Biotech Stock Up 7.1 %

The company has a market cap of $55.93 million, a P/E ratio of -1.82 and a beta of 0.55. The firm’s 50-day moving average price is $6.54 and its 200-day moving average price is $5.26.

Institutional Investors Weigh In On Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Crcm LP acquired a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 325,969 shares of the company’s stock, valued at approximately $2,200,000. Burning Rock Biotech makes up about 0.9% of Crcm LP’s investment portfolio, making the stock its 5th largest position. Crcm LP owned 3.18% of Burning Rock Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.